Average Co-Inventor Count = 4.96
ph-index = 19
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Synaptic Pharmaceutical Corporation (20 from 126 patents)
2. Gilead Pharmasset LLC (14 from 79 patents)
3. Rhizen Pharmaceuticals Sa (14 from 51 patents)
4. Bayer Pharmaceuticals Corporation (5 from 70 patents)
5. Bayer Healthcare LLC (4 from 780 patents)
6. Gilead Sciences, Inc. (2 from 919 patents)
7. Merck + Co., Inc. (1 from 4,770 patents)
8. Smithkline Beecham Corporation (1 from 2,198 patents)
9. Gilead Pharmassel LLC (1 from 1 patent)
61 patents:
1. 12121529 - Nucleoside phosphoramidate prodrugs
2. 11642361 - Nucleoside phosphoramidate prodrugs
3. 11066402 - 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
4. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases
5. 10981919 - Selective PI3K delta inhibitors
6. 10570142 - Selective PI3K delta inhibitors
7. 10322130 - Substituted chromenones as modulators of protein kinases
8. 10220035 - Compounds as modulators of protein kinases
9. 10183037 - Nucleoside phosphoramidate prodrugs
10. 10072013 - Selective PI3K delta inhibitors
11. 9815831 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
12. 9777018 - Compounds as modulators of GPR-119
13. 9775841 - Compounds as modulators of protein kinases
14. 9669033 - Selective PI3K delta inhibitors
15. 9585906 - Nucleoside phosphoramidate prodrugs